UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 6-K



REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

Date: May 15, 2024
Commission File Number: 001-41338


IperionX Limited
(Translation of registrant’s name into English)



129 W Trade Street, Suite 1405
Charlotte, North Carolina
(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐



EXHIBIT INDEX

The following exhibits are filed as part of this Form 6-K:

Exhibit
 
Description
   
 
Press Release


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
IPERIONX LIMITED
 
(registrant)
   
Date: May 15, 2024
By:  /s/ Marcela Castro
 
Name: Marcela Castro
 
Title:   Chief Financial Officer




Exhibit 99.1

PRESS RELEASE | NASDAQ: IPX | ASX: IPX
May 15, 2024

Not for release to US wire services or distribution in the United States
 
IPERIONX COMPLETES A$50 MILLION PLACEMENT TO SCALE U.S. TITANIUM MANUFACTURING CAPACITY
 
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) is pleased to announce that it has received firm commitments for a placement of 26.2 million new fully paid ordinary shares at an issue price of A$1.91 per share (New Shares) to raise gross proceeds of A$50.0 million (approximately US$33.0 million) before costs (Placement).
 
Proceeds from the Placement will be used to scale titanium manufacturing capacity at IperionX’s operations in Virginia, including new equipment at the Advanced Manufacturing Center, final design, and engineering studies to increase titanium production capacity to ~2,000 metric tons per annum at the Titanium Production Facility, and for general working capital and corporate purposes.
 
Executive Chairman of IperionX, Mr. Todd Hannigan, has subscribed for 3.2 million New Shares to raise A$6.1 million (approximately US$4.0 million) under the Placement, and Non-Executive Director, Ms. Lorraine Martin, has subscribed for 0.2 million New Shares to raise A$0.3 million (approximately US$0.2 million), subject to shareholder approval.
 
The issue price of A$1.91 per New Share represents a 10% discount to the last closing price of A$2.12.
 
As a result of the planned participation by Directors, the Placement will be completed in two tranches as follows:
 
(a)
22.9 million New Shares will be issued on or about Wednesday, 22 May 2024 under Listing Rule 7.1; and
 
(b)
3.3 million New Shares will be issued to Directors subject to shareholder approval to be sought at a General Meeting of the Company’s shareholders. A notice of meeting will be sent to shareholders shortly to approve the Directors participation.
 
Bell Potter Securities Limited was Lead Manager and Bookrunner to the Placement. Canaccord Genuity (Australia) Limited was Co-Manager to the Placement.
 
This announcement has been authorized for release by the Board of Directors.
 
For further information and enquiries please contact:
 
info@iperionx.com 
+1 704 461 8000
 
Not an offer in the United States
 
This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.
 
North Carolina
Tennessee
Virginia
Utah
129 W Trade Street, Suite 1405
Charlotte, NC 28202
279 West Main Street
Camden, TN 38320
1080 Confroy Drive
South Boston, VA 24592
1782 W 2300 S
West Valley City, UT 84119


About IperionX
 
IperionX aims to become a leading American titanium metal and critical materials company – using patented metal technologies to produce high performance titanium alloys, from titanium minerals or scrap titanium, at lower energy, cost and carbon emissions.
 
Our Titan critical minerals project is the largest JORC-compliant mineral resource of titanium, rare earth and zircon minerals sands in the United States.
 
IperionX’s titanium metal and critical minerals are essential for advanced U.S. industries including space, aerospace, defense, consumer electronics, hydrogen, electric vehicles and additive manufacturing.
 
 
Forward Looking Statements

Information included in this release constitutes forward-looking statements. Often, but not always, forward looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “continue”, and “guidance”, or other similar words and may include, without limitation, statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs or production outputs.

Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, and achievements to differ materially from any future results, performance, or achievements. Relevant factors may include, but are not limited to, changes in commodity prices, foreign exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative nature of exploration and project development, including the risks of obtaining necessary licenses and permits and diminishing quantities or grades of reserves, the Company’s ability to comply with the relevant contractual terms to access the technologies, commercially scale its closed-loop titanium production processes, or protect its intellectual property rights, political and social risks, changes to the regulatory framework within which the Company operates or may in the future operate, environmental conditions including extreme weather conditions, recruitment and retention of personnel, industrial relations issues and litigation.

Forward looking statements are based on the Company and its management’s good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company’s business and operations in the future. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove to be correct, or that the Company’s business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company’s control.

Although the Company attempts and has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in forward looking statements, there may be other factors that could cause actual results, performance, achievements, or events not to be as anticipated, estimated or intended, and many events are beyond the reasonable control of the Company. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements in these materials speak only at the date of issue. Subject to any continuing obligations under applicable law or any relevant stock exchange listing rules, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
 




IperionX (NASDAQ:IPX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more IperionX Charts.
IperionX (NASDAQ:IPX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more IperionX Charts.